A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
231 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Buenos Aires, Argentina
- Research Site
CABA, Argentina
- Research Site
CABA, Argentina
- Research Site
La Plata, Argentina
- Research Site
Pergamino, Argentina
- Research Site
Rosario, Argentina
- Research Site
San Salvador de Jujuy, Argentina
- Research Site
Viedma, Argentina
- Research Site
Graz, Austria
- Research Site
Innsbruck, Austria
- Research Site
Rankweil, Austria
- Research Site
Vienna, Austria
- Research Site
Vienna, Austria
- Research Site
Ghent, Belgium
- Research Site
Liège, Belgium
- Research Site
Mons, Belgium
- Research Site
Barretos, Brazil
- Research Site
Belo Horizonte, Brazil
- Research Site
Campinas, Brazil
- Research Site
Curitiba, Brazil
- Research Site
Florianópolis, Brazil
- Research Site
Natal, Brazil
- Research Site
Porto Alegre, Brazil
- Research Site
Santa Maria, Brazil
- Research Site
São José do Rio Preto, Brazil
- Research Site
São Paulo, Brazil
- Research Site
São Paulo, Brazil
- Research Site
Teresina, Brazil
- Research Site
Vitória, Brazil
- Research Site
Plovdiv, Bulgaria
- Research Site
Sofia, Bulgaria
- Research Site
Sofia, Bulgaria
- Research Site
Sofia, Bulgaria
- Research Site
Edmonton, Alberta, Canada
- Research Site
Kitchener, Ontario, Canada
- Research Site
Lévis, Quebec, Canada
- Research Site
Montreal, Quebec, Canada
- Research Site
Montreal, Quebec, Canada
- Research Site
Québec, Quebec, Canada
- Research Site
Saskatoon, Saskatchewan, Canada
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 6 Dec 2018
- Primary completion
- 10 Nov 2022
- Completion
- 11 Sept 2028
- Last update posted
- 11 Jun 2025
- Registered enrollment
- 825
- Registry id
- NCT03800134
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.